Clinical Trial Update: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (ACTION) evaluating ONC201 for H3 K27M-mutant diffuse glioma following radiotherapy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Midline Glioma H3 K27-altered

Drugs mentioned

• ONC201 (ONC201)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: H3 K27M, Glioma | Phase 3 | Status: RECRUITING